New study aims to make breast cancer treatment easier to tolerate
NCT ID NCT06001762
First seen Jan 17, 2026 · Last updated May 16, 2026 · Updated 15 times
Summary
This study tests whether slowly increasing the dose of the drug abemaciclib can cause fewer side effects than the standard dose in people with early-stage, hormone receptor-positive breast cancer. About 90 participants will take the drug along with standard hormone therapy. The goal is to see if this approach helps more people stay on treatment without needing to stop or lower their dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY STAGE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Boston Medical Center
Boston, Massachusetts, 02118, United States
-
Dana-Farber Cancer Insitute at Londonderry Hospital
Londonderry, New Hampshire, 03053, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute at Foxborough
Foxborough, Massachusetts, 02035, United States
-
Dana-Farber Cancer Institute at Merrimack Valley
Methuen, Massachusetts, 01844, United States
-
Dana-Farber Cancer Institute at Milford
Milford, Massachusetts, 01757, United States
-
Dana-Farber Cancer Institute at South Shore
South Weymouth, Massachusetts, 02190, United States
-
Dana-Farber Cancer Institute at Steward St. Elizabeth's
Brighton, Massachusetts, 02135, United States
-
Eastern Maine Medical Center (Northern Light)
Brewer, Maine, 04412, United States
-
New England Cancer Specialists
Scarborough, Maine, 04074, United States
-
Stamford Hospital
Stamford, Connecticut, 06904, United States
Conditions
Explore the condition pages connected to this study.